Pfizer Inc. (NYSE:PFE) Shares Acquired by Monterey Private Wealth Inc.

Monterey Private Wealth Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 16.4% during the second quarter, HoldingsChannel reports. The fund owned 6,172 shares of the biopharmaceutical company’s stock after acquiring an additional 871 shares during the quarter. Monterey Private Wealth Inc.’s holdings in Pfizer were worth $324,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Pfizer by 3.0% during the first quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock worth $24,801,210,000 after acquiring an additional 13,790,348 shares during the period. State Street Corp boosted its holdings in Pfizer by 0.7% during the first quarter. State Street Corp now owns 286,854,205 shares of the biopharmaceutical company’s stock worth $14,850,442,000 after buying an additional 2,037,373 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 13.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after buying an additional 6,972,650 shares in the last quarter. Norges Bank purchased a new stake in Pfizer during the fourth quarter worth about $3,351,891,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Pfizer by 28.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock worth $2,246,359,000 after buying an additional 9,537,621 shares in the last quarter. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. The Goldman Sachs Group set a $50.00 price objective on shares of Pfizer in a report on Thursday, September 1st. UBS Group set a $59.00 price target on shares of Pfizer in a report on Thursday, September 1st. Berenberg Bank set a $44.00 price target on shares of Pfizer in a report on Wednesday, September 14th. Barclays set a $50.00 price target on shares of Pfizer in a report on Thursday, September 1st. Finally, JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a report on Tuesday, June 28th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $57.00.

Pfizer Stock Performance

Shares of PFE stock opened at $44.57 on Friday. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. The company has a 50 day moving average price of $48.40 and a 200 day moving average price of $50.33. The firm has a market capitalization of $250.14 billion, a price-to-earnings ratio of 8.72, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.95 by $0.09. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The firm had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. During the same quarter in the prior year, the business posted $1.07 earnings per share. Pfizer’s revenue for the quarter was up 46.8% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 6.54 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.59%. Pfizer’s dividend payout ratio (DPR) is 31.31%.

Pfizer Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.